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Recruitment to cancer clinical trials needs to be improved, as does patient knowledge and understanding about clinical trials, in order
for patients to make an informed choice about whether or not to take part. Audiovisual patient information (AVPI) has been shown
to improve knowledge and understanding in various areas of practice, but there is limited information about its effect in the cancer
clinical trial setting, particularly in relation to consent rates. In this study, 173 patients were randomised to receive either the AVPI, in
addition to the standard trial-specific written information, or the written information alone. There was no difference in clinical trial
recruitment rates between the two groups with similar study entry rates: 72.1% in the AVPI group and 75.9% in the standard
information group. The estimated odds ratio for refusal (intervention/no intervention) was 1.19 (95% CI 0.55–2.58, P¼0.661).
Knowledge scores increased more in the AVPI group compared to the standard group (P¼0.0072). The change in anxiety score
between the arms was also statistically significant (P¼0.011) with anxiety improving in the intervention arm more than in the no
intervention arm. Audiovisual patient information was shown to be a useful tool in improving patient knowledge and anxiety, but
further work is necessary in relation to its effect on clinical trial recruitment rates.
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Clinical trials and recruitment
Clinical trials are the only safe and effective way to improve
treatments for cancer. However, less than 5% of patients are
recruited to cancer clinical trials every year due to a variety of
reasons as discussed in detail by Fayter et al (2006). There are
factors surrounding the patient, trial and physician with some
potentially modifiable, such as issues around the informed consent
process and patient refusal. Meeting patients’ information needs and
obtaining truly informed consent is challenging in cancer, especially
in relation to clinical trials, due to the vulnerability of patients and
the complexity of treatments. Misconceptions about clinical trials
are common, particularly in relation to randomisation.
Although there are discreet scientific and ethical challenges in
each phase of clinical trial, the randomised phase III trial has been
shown to be particularly problematic in relation to misinterpreta-
tion and poor understanding of patient information, often in
relation to the concept of randomisation (Sutherland et al, 1990;
Lovato et al, 1997; Featherstone and Donovan, 2002). Compared
with earlier phase studies (Gordon and Daugherty, 2001), relatively
high rates of patient refusal have been reported: 28% (Jenkins and
Fallowfield, 2000), 40% (Klabunde et al, 1999) and 49% (Lara et al,
2001). Research undertaken in ‘hypothetical trial’ situations of
chemotherapy have shown refusal rates of 40% (Sutherland et al,
1990) and 58% (Llewellyn-Thomas et al, 1991). Randomised phase
III trials comprise the largest component of clinical research in
terms of both the number of trials being carried out and also in
relation to the number of patients taking part. These trials are
therefore of major interest in tackling the worldwide issue of low
recruitment to cancer clinical trials.
Knowledge, understanding and decision making about
clinical trials
Knowledge and understanding appear to be related to patient
decision making concerning clinical trials, although study findings
are conflicting. For example, Simes et al (1986) found that patients
with a better understanding were less likely to agree to
randomisation. However, in another study, Ellis et al (2001) found
that women who had a better understanding of clinical trial
information have more favourable attitudes towards them and are
more willing to consider participating.
Fear of randomisation and preference for the doctor to choose
the treatment was highlighted as one of the reasons patients’
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sdeclined cancer trial participation in the study by Jenkins and
Fallowfield (2000). But, as acknowledged by the authors, it is not
clear if patients declined because they did not understand the
concept of randomisation or because they did, and that evidence
from other studies suggest that it is likely to be related to not
understanding the concept (Sutherland et al, 1990).
Knowledge and anxiety
Patient anxiety levels are often high due to a number of issues
including having a recent cancer diagnosis and cancer treatment
(Kelly et al, 2002). In most cases, anxiety is part of a normal
reaction to cancer. Although appropriate treatment for anxiety is
to provide adequate information and support (Kelly et al, 2002),
the impact on anxiety levels, of increasing knowledge as in the
clinical trial situation, is conflicting. Some studies have found that
patients with better knowledge and understanding were more
anxious (Simes et al, 1986), but the majority of studies have found
patient anxiety to be unchanged or reduced (Ellis et al, 2001).
Audiovisual patient information
Audiovisual patient information (AVPI) has been shown to
improve knowledge and understanding without increasing anxiety
(Luck et al, 1999; Mason et al, 2003), to influence behaviour
(Sherafat et al, 2003) and to assist patients with decision making
(McGregor, 2003). In oncology, video and CD-ROM both have
been shown to be acceptable and useful mediums for information
transfer (Thomas et al, 2000; Agre et al, 2002). In the clinical trial
setting, video has been shown to improve the consent process
(Wirshing et al, 2005). However, limited information is available
on the effect of AVPI on clinical trial recruitment rates.
Weston et al (1997) looked hypothetically at ‘interest in
participation’ in a perinatal trial and concluded that a patient
information video combined with an information sheet may result
in greater participation. However, they acknowledged the
hypothetical situation and that it was not possible to know if it
translated into improved recruitment for this trial.
Daugherty et al (2003) studied the effect of a CD-ROM
educational intervention for advanced cancer patients enrolling
in phase I and phase II trials and developed an interactive CD-
ROM. Patients were randomised to either view the CD-ROM or
receive a written information leaflet. Of those who completed the
CD-ROM, 71% subsequently enrolled in a trial compared with 58%
who received the written information. Although this was a very
specific patient population – advanced cancer, and a unique trial
setting (phases I and II) – the same issues of vulnerable cancer
patients and complex trial information exist for patients consider-
ing participation in randomised cancer clinical trials.
Methods such as video, CD-ROM and DVD offer an opportunity
to provide generic information about randomised clinical trials to
address common misconceptions and misinterpretations, along
with cancer site-specific trial information, in an acceptable and
effective manner, as a supplement to the written information
routinely given to patients considering clinical trials. The limited
work that has been carried out in relation to audiovisual aids and
clinical trials suggests a positive effect on consent rates, but further
work is necessary which led to the impetus for this study.
PATIENTS AND METHODS
Study aims
The main aims of the study were
(1) to determine the effect of an AVPI intervention on
(a) refusal rates to randomised cancer trials
(b)knowledge and anxiety and
(2) to investigate patients’ perceptions of the AVPI.
Reasons for accepting and declining trial participation were also
investigated and will be reported in a future paper.
Ethics approval was obtained from the West Research Ethics
Committee.
Sample
Patients were eligible for the study if they
  had a diagnosis of colorectal, breast or lung cancer and were
clinically eligible for entry into a cancer treatment trial
randomised against control/standard treatment, or best suppor-
tive care,
  had access to a video recorder, CD-ROM or DVD playing
facilities and
  could understand English.
Clinical trials for breast, lung and colorectal cancer that involved
randomisation against control/standard treatment, or best sup-
portive care, running at the cancer centre, were included in the
study.
The primary study end point was the percentage of patients in
the study who declined participation in the clinical trial that was
presented to them. On the basis of the literature, it was assumed
that 40% of patients refuse participation in cancer clinical trials,
and in order to have an 80% chance of detecting a 20% difference
at the 5% significance level (two-sided), a total of 164 patients were
required. This number would detect a reduction in refusal rate
from 40 to 20%. This sample size also provides approximately 80%
power to detect a moderate standardised difference of 0.45 between
continuous variables such as knowledge and anxiety scores.
The study was initially introduced to the patient by their
clinician, during explanation of the clinical trial. Following
consent, patients were randomised to intervention or no interven-
tion (1:1) by contacting the CRUK Clinical Trials Unit (CTU). The
study was stratified for individual trial, tumour type, age and sex
using the minimisation method, which was implemented in the
CTU’s Oracle database.
Data collection and analysis
Data were collected from patient case notes and directly from
questionnaires. Patients were seen on two occasions for the
purposes of this study. These visits were part of patients’ general
medical care, as they were attending the hospital anyway on these
days. These were known as ‘visit 1’ (explanation of treatment trial)
and ‘visit 2’ (return visit, usually 1 week later, to discuss decision).
Measures/instruments
Log sheet: Demographic data on all patients who were ap-
proached for the AVPI study were collected and entered into a log
sheet. Deprivation status was determined using deprivation
categories measured by the Carstairs scores for Scottish postcode
sectors (Carstairs and Morris, 1991) using data from the 2001
census (McLoone, 2004).
Clinical Trial Decision Questionnaire: The Clinical Trial Decision
Questionnaire is a two-page self-report to assess patients’ reasons
for accepting or refusing participation in the trial, perceptions of
the consent process and value of the video/CD-ROM/DVD.
Patients completed this at visit 2 only. Reasons for accepting/
declining the trial were the main focus of this questionnaire. It
includes the questionnaire used by Jenkins and Fallowfield (2000)
(with kind permission from Dr V Jenkins). Questions in relation to
the consent process and usefulness of the video were derived from
the literature and consultation with a panel of experts – clinicians
and clinical trials nurses – to ensure content validity. The majority
of findings from analysis of this questionnaire will be discussed in
AV patient information in cancer clinical trials
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sa future paper focusing on factors affecting decision making in
randomised cancer trials.
Knowledge questionnaire: This was a new 12-item questionnaire
derived from the literature, patient and professional consultation,
for the purpose of this study and has been tested as described in a
previous study resulting in slight changes before usage in this
study (Hutchison et al, 2007). Patients completed this question-
naire at baseline (visit 1) and at visit 2.
Spielberger State and Trait Anxiety Inventory: The Spielberger
State and Trait Anxiety Inventory-S assesses anxiety in relation to
how one feels at the moment (state). Anxiety was assessed at the
same time as knowledge (both visit 1 and visit 2).
Intervention The control arm of the study involved current
standard practice in the department for discussing clinical trials
with patients. Patients see either a registrar or consultant from the
tumour site team, who discusses the trial and administers a trial-
specific information sheet and consent form (visit 1). An
appointment is then made for them to return to clinic the
following week. At this visit (visit 2), they see a clinician from the
same team to decide on treatment and whether or not this will be
part of a clinical trial.
The intervention consisted of an AVPI tool, which addressed
both generic and cancer site-specific clinical trial information, with
a particular focus on the concept of randomisation. Areas covered
in the AVPI include how drugs/treatments are developed,
importance of clinical trials, what randomised trials are and when
they are carried out, criteria for taking part, benefits/disadvantages
of taking part in a randomised trial, funding issues, voluntariness
of decision and freedom to withdraw at any time. ‘Randomisation’
is described by the actress-presenter by using flip charts with
pictures of bags of chemotherapy as a visual aid. Within the
production, to try to assist in understanding the randomisation
concept, several examples of types of randomised trials are given,
including a trial where one of the arms is ‘best supportive care’.
There are pictures of patients receiving treatment and a voice-over
describing the main principles such as that of uncertainty about
which treatment is best and also emphasising that the doctor does
not decide which treatment the patient will get. At the end of the
AVPI, the presenter encourages patients to consider their decision
carefully about whether or not to take part, reassuring them that
whatever they decide, it will be fully supported by their clinical
team. She then refers them to their trial-specific information sheet
for further information.
The AVPI was given in addition to standard practice as
described in the control arm of the study. The AVPI was developed
by clinical and technical staff within the department via a
multiprofessional team. Three different versions were made (lung,
breast and colorectal cancer) with the same core content, which
lasted 10min in total. Patients were given the AVPI to watch at
home: there were three different formats (video, CD-Rom, DVD) to
allow for patient preference and availability of equipment at home.
The process of developing the AVPI is described in detail
elsewhere (Hutchison and McCreaddie, 2007).
Analysis The main comparison of the primary end point between
the study arms was performed using logistic regression using all
randomised patients. An attempt was made to incorporate
minimisation factors used at the time of randomisation into the
logistic regression, but the high degree of confounding between
gender, tumour type and study meant that of these only gender
could be used. The odds ratio was derived from the logistic
regression and the P-value for the comparison was derived by the
likelihood ratio method. The association between baseline patient
characteristics and study entry was also assessed in the context of a
logistic regression model.
The change in knowledge score from baseline was compared
between the two groups via a Mann–Whitney U-test (the
knowledge score is the number of correctly answered questions
expressed as a percentage mark). The statistical significance of
within patient changes in knowledge score in each group was
assessed using the Wilcoxon signed rank sum test. An assessment
of the prognostic value of various baseline characteristics for
change in knowledge score was assessed in the context of a linear
model incorporating study arm; the dependence of the prognostic
value on study arm was assessed by incorporating the appropriate
interaction term. Multiple imputation (Rubin, 1987) was applied to
assess the robustness of the results of these analyses to missing
data. Bootstrap methods were used to estimate the difference in
median changes and associated 95% confidence intervals. The
association between baseline characteristics and baseline knowl-
edge levels was assessed using the Mann–Whitney U-test (2
categories), Kruskal–Wallis test (42 categories) or, for age,
Spearman’s rank correlation.
A parallel analysis to that described for the knowledge score was
conducted for the anxiety score.
RESULTS
Demographic and baseline characteristics
There were 244 patients identified for the AVPI study, of which 13
were not approached as they were considered to be particularly
distressed due to being told bad news or experiencing uncontrolled
symptoms from their disease. Of the 231 patients who were
approached for the study, 173 patients were recruited during the
study period of 19 months (January 2005 to August 2006). Two
patients were excluded as they did not have access to a video,
computer or DVD player. Thus, the refusal rate for this study was
24% (56 out of 229) and included a variety of reasons given by
patients, such as they had already made their decision, they felt too
upset and they did not want any further information. Of those who
refused to take part in this study, only 27% were entered into the
clinical trial offered. Patients were entered into a total of 18
different randomised clinical trials during the study period.
Although the target number was 164, extra patients were recruited
to allow for the proportion of patients for whom the question of
trial entry at visit 2 was no longer applicable as they were no longer
eligible or, for administrative reasons, the study was no longer
available. Baseline characteristics of those recruited to this study
were well balanced between the arms, as shown in Table 1.
The majority of patients – 56% (48 out of 86) – chose DVD as
their preferred medium for the intervention with 43% (37 out of
86) choosing video and 1% (1 out of 86) CD-ROM.
Primary end point: clinical trial refusal rate
The primary end point was the proportion of patients refusing
clinical trial entry. An intention-to-treat analysis including all
patients (and adjusting for baseline minimisation factors age and
gender) gives an estimated odds ratio for refusal (intervention/no
intervention) of 1.19 (P¼0.661, 95% CI 0.55–2.58). Although
patient refusal was the main reason that patients did not enter
clinical trials, 3.5% of patients were then not eligible for the clinical
trial and seven patients (4%) did not enter for ‘other’ reasons.
These were mainly for reasons of disease progression. Excluding
patients who were either not eligible for the trial or could not enter
for some other reason gives an odds ratio for refusal of 1.19
(P¼0.664, 95% CI 0.54–2.60). Table 2 summarises the proportion
of patients who subsequently entered into clinical trials.
There were no statistically significant (P40.05) associations
between any of the pretreatment patient characteristics as reported
in Table 1 and clinical trial entry, nor was there any statistically
AV patient information in cancer clinical trials
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ssignificant interaction between the study arm and these character-
istics. There were no statistically significant differences in the
reasons given on the decision questionnaire between the two arms
either for those who accepted trial entry or those who refused trial
entry.
Knowledge questionnaire
In the intervention arm, 81 patients completed the baseline
questionnaire and 77 the follow-up questionnaire; the correspond-
ing figures in the no intervention arm are 82 and 77. Seventy-three
patients in each arm completed the questionnaire at both time
points. The difference in the change in percentage score is
statistically significant between the treatment arms (P¼0.011,
P¼0.0072 (multiple imputation)) with improvements in the
knowledge score tending to be higher in the intervention arm.
The estimated difference in the median knowledge change score
between the groups is 5.0 (95% CI 0.0–16.7). Within both arms,
there is a statistically significant improvement in score from pre to
post (Po0.001 and Po0.001 (multiple imputation) in both arms).
The distribution of the percentage knowledge score for these
patients is shown in Figure 1. Change in knowledge level does not
appear to be associated with probability of refusing clinical trial
entry.
Age (P¼0.004), stage (Po0.001), friend/family member in
research study (P¼0.015), educational qualifications (Po0.001)
and tumour type (P¼0.028) all have statistically significant
associations with knowledge at baseline. A multivariate logistic
regression (knowledge score dichotomised at the median, variables
selected by a forward-stepwise method) was undertaken to
examine which pretreatment characteristics were independently
associated with baseline knowledge. The outcome of this analysis
indicated that education and stage of disease independently were
associated with baseline knowledge. Patients who were better
educated had higher levels of knowledge (P¼0.001). Patients who
had limited stage of cancer had higher baseline knowledge when
compared with patients with advanced cancer (Po0.001). Change
in knowledge scores did not show any statistically significant
association with any of the baseline characteristics in models
where the effect of study arm was included, nor was there any
Table 1 Demographic and baseline characteristics
Study arm Overall total
Intervention No intervention
Col % Count Col % Count Col % Count
Gender
F 76.7 66 77.0 67 76.9 133
M 23.3 20 23.0 20 23.1 40
Group total 100.0 86 100.0 87 100.0 173
Tumour type
Breast 65.1 56 64.4 56 64.7 112
Colorectal 31.4 27 32.2 28 31.8 55
Lung 3.5 3 3.4 3 3.5 6
Group total 100.0 86 100.0 87 100.0 173
Age group
o50 22.1 19 20.7 18 21.4 37
50–59 23.3 20 24.1 21 23.7 41
60–69 39.5 34 37.9 33 38.7 67
4¼70 15.1 13 17.2 15 16.2 28
Group total 100.0 86 100.0 87 100.0 173
Stage of cancer
Limited 68.6 59 66.7 58 67.6 117
Advanced 31.4 27 33.3 29 32.4 56
Group total 100.0 86 100.0 87 100.0 173
Educational qualifications
None 22.2 18 26.3 21 24.2 39
Below degree level 48.1 39 45.0 36 46.6 75
Degree level or higher 29.6 24 28.8 23 29.2 47
Group total 100.0 81 100.0 80 100.0 161
Previously taken part in research study
Yes 8.3 7 15.7 13 12.0 20
No 91.7 77 84.3 70 88.0 147
Group total 100.0 84 100.0 83 100.0 167
Friend/family member been in research study
Yes 12.0 10 12.2 10 12.1 20
No 88.0 73 87.8 72 87.9 145
Group total 100.0 83 100.0 82 100.0 165
Deprivation status
Affluent 27.4 23 27.6 24 27.5 47
Middle 46.4 39 37.9 33 42.1 72
Deprived 26.2 22 34.5 30 30.4 52
Group total 100 84 100 87 100.0 171
Table 2 Proportion of patients that subsequently entered into clinical
trials
Study arm Group total
Intervention No intervention
Col % Count Col % Count Col % Count
Entered into trial?
Yes 72.1 62 75.9 66 74.0 128
No, refused 19.8 17 17.2 15 18.5 32
No, not eligible 2.3 2 4.6 4 3.5 6
No, other 5.8 5 2.3 2 4.0 7
Group total 100.0 86 100.0 87 100.0 173
No intervention Intervention
Study arm
0.00
20.00
40.00
60.00
80.00
100.00
Pre-knowledge
score
Post-knowledge
score
Figure 1 Distribution of percentage knowledge score for patients
completing questionnaires at both time points.
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baseline characteristics.
Anxiety questionnaire
In the intervention arm, 77 patients completed the baseline
questionnaire and 73 the follow-up questionnaire; the correspond-
ing figures in the no intervention arm are 79 and 69. Sixty-seven
patients on the ‘intervention’ arm completed anxiety question-
naires at both time points. On the ‘no intervention’ arm the
number was 65. There is a statistically significant difference in
anxiety score pretreatment (P¼0.006), with patients in the
‘intervention’ arm appearing to be more anxious than in the ‘no
intervention’ arm.
The change in anxiety score between the arms is statistically
significant (Po0.001 and P¼0.011 (multiple imputation)) with
anxiety improving in the ‘intervention’ arm more than in the ‘no
intervention’ arm. The estimated difference in the median anxiety
change score between the groups is  4.6 (95% CI  7.0 to  2.0).
Because of the elevated anxiety in the ‘intervention’ group
pretreatment, this means that anxiety levels in the two groups
are similar at the ‘post’-assessment. The change from pre to post
within the ‘intervention’ group is highly statistically significant
(Po0.001 and Po0.001 (multiple imputation)); there was no
statistically significant change in the ‘no intervention’ group
(P¼0.462 and P¼0.408 (multiple imputation)). The distribution
of the anxiety score is shown in Figure 2.
There was no significant association with any of the pretreat-
ment patient characteristics, as reported in Table 1, and anxiety.
Change in anxiety scores did not show any statistically significant
association with any of the baseline characteristics in models
where the effect of study arm was included, nor was there any
indication that the effect of study arm was influenced by any of the
baseline characteristics.
Patients’ perceptions of the video/CD-ROM/DVD
Seventy-three patients responded to the questions about their
perceptions of the AVPI. Of the patients who received it, 96% (70
out of 73) watched it. Of those who watched it, overall 93% (65 out
of 70) found it useful. When asked about the effect the AVPI had
on their decision about whether or not to take part in the clinical
trial, 42% (25 out of 60) of those who entered the trial said that it
had made them want to take part. A large proportion of patients
overall stated that the AVPI had no effect on their decision about
whether or not to take part in the clinical trial; this was 90% (9 out
of 10) of those who refused trial entry and 57% (34 out of 60) of
those who entered the trial.
DISCUSSION
The results showed that although the AVPI had no effect on refusal
rates to the randomised cancer trials that the patients were offered,
it did have a positive effect on levels of knowledge about clinical
trials. It also appeared to reduce anxiety, although there was a
statistically significant imbalance in baseline anxiety levels
between the two groups, for which we could find no obvious
explanation other than the play of chance. In addition, the AVPI
was perceived by patients to be a useful adjunct to the informed
consent process.
The study was designed with an assumed clinical trial refusal
rate of 40% which was based on an average from previous studies
(Klabunde et al, 1999; Jenkins and Fallowfield, 2000; Lara et al,
2001). However, the observed refusal rate for clinical trials in this
study of approximately 20% is substantially less than that reported
in the literature. Interestingly, the UK study by Jenkins and
Fallowfield (2000) reported a refusal rate of 25–28% and, like this
study, focused on randomised cancer trials and also had a
relatively high proportion of patients with breast cancer.
In our study, the relatively low refusal rate to clinical trials can
perhaps be explained within the context of refusal rates for this
study where the rate was also low at 24%. Therefore, it could be
that the sample was not wholly representative of the population
under study. Of those who refused the AVPI study, 73% did not
then go into the clinical trial. This is a much higher proportion
than the patients who did not enter (for reasons of patient refusal
or ineligibility) in both arms of the AVPI study: intervention arm
27.9%; control arm 24.1% (Table 2).
A particular challenge in the informed consent process for
clinical trials is to access the patients who have already made their
decision about whether or not to take part in the trial, before
receiving any information or discussion about it. They are often
unwilling to even consider the information, an issue that is difficult
in any research study. This would perhaps be easier if AVPI was
standard practice in the consent process for clinical trials and was
presented to the patient as part of their routine care, although it is
acknowledged that there would still be some patients who would
choose not to view it.
Garcea et al (2005) found differences in attitudes between
patients with primary colorectal cancer and patients with
secondary colorectal cancer and their willingness to participate
in drug trials. They found that more advanced stage patients were
more likely to say yes to a clinical trial (56 vs 22%). This finding
was not substantiated by our study where there were no significant
differences in consent rates associated with stage of disease,
despite the finding that at baseline, those with limited stage disease
were found to be more informed (Po0.001). Increase in knowl-
edge did not make people more likely to participate.
A generic approach to information in the AVPI was adopted to
focus on the concept of randomization, which was effective in
terms of improving patient knowledge and understanding as
hoped, but did not improve consent rates. In an attempt to make a
generic approach more relevant to the individual patient, the AVPI
was customised to tumour type, but it may be that a more specific
approach is required. The AVPI could be made specific to an
individual trial, although to achieve this would have substantial
practical challenges. Wallace et al (2006) have shown that in
20.00
30.00
40.00
50.00
60.00
70.00
80.00 Pre-anxiety score
Post-anxiety score
No intervention Intervention
Study arm
Figure 2 Distribution of percentage anxiety score for patients
completing questionnaires at both time points.
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sa ‘difficult’ randomised trial with very different treatment options, a
multiprofessional education session with patients, which included
viewing a customised video, did increase clinical trial consent rates.
An important finding for the cancer trial setting, which is
consistent with previous work (predominantly from other
specialities), was the effectiveness of AVPI in improving knowl-
edge and understanding without increasing anxiety (Luck et al,
1999; Mason et al, 2003). It was also encouraging that within both
groups, patients were more knowledgeable following the patient
information-giving process.
The AVPI was well received, with the majority of patients
finding it useful. Only two patients were excluded from the study
because they did not have a computer, video or DVD player, which
shows that the technology is widely available in patients’ homes.
Less than half felt that the AVPI affected their decision about
whether or not to take part, which is interesting as other authors
have also reported that in decision-making situations, patients
relied more on the consultation and the influence/advice of the
clinician and less on the supporting tools (Penman et al, 1984).
However, the literature is conflicting and Garcea et al (2005)
found, in their study of patients with colorectal cancer, that over
90% claimed to have made their decision after reading the patient
information leaflet.
Although the study has provided useful information for practice,
its limitations must be acknowledged. It was carried out at a
regional cancer centre and findings may not generalise to patients
being seen in different settings. The sample consisted of a
particularly high number of patients with breast cancer and
patients were recruited from a total of 18 different clinical trials.
This number of trials could be considered an advantage in terms of
generalisability, but could also be seen as a limitation as it was not
possible to say with any confidence if there were differences in
patients’ decisions between studies, as a result of factors within the
trials themselves, for example trials with very different arms where
patients may have a preference. Patients’ attitudes were not
assessed in this study and it would have been interesting to
determine if attitudes changed as a result of the intervention.
In addition, physician interpersonal skills and quality of the
interaction have not been addressed in this study. Further work in
this area is needed as it has been suggested that these factors may
have more of an influence on clinical trial recruitment and that
clinical trial acceptance does not appear to be based on a rational
model of decision making (Curbow et al, 2006). If this is the case,
then it is unlikely that consent rates to clinical trials will increase
by improving patient knowledge and understanding.
CONCLUSIONS
Despite the limitations, findings from this study support the use of
AVPI as a useful addition to the consent process for randomised
cancer trials in terms of improving patient knowledge and
understanding before decision making. It appears to reduce
anxiety at this time point and has been shown to be an acceptable
medium for patients. In this study, AVPI was not shown to have
any effect on refusal rates to randomised cancer trials. Further
work focusing on AVPI specific to individual trials would be
helpful to determine if a more customised approach would be of
benefit in relation to clinical trial recruitment.
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